Heparegenix
HepaRegeniX is a clinical-stage biotech company developing a therapeutic concept to treat acute and chronic liver diseases by reversing disease paths through liver regeneration. The company is advancing its lead drug candidate, darizmetinib (HRX215), which is currently in Phase 1b clinical trials for patients undergoing liver resection. Its primary focus is on enhancing liver regeneration to cure various liver-related conditions.
Biotech
Healthcare
Pharmaceuticals
Funding summary
- Total raised
- €11.0M
- Funding rounds
- 1
Investors in Heparegenix
Investors on record for Heparegenix. Click any investor to view their CAPLINK profile and funding criteria.
Fundraising for a startup like Heparegenix?
Explore CAPLINK's investor database of thousands of active VCs and angels.
Browse investors